65,437 trials
Heart Failure
Primary: Venous Angiotensin II Levels After 12 Weeks of Treatment — 0.91; 1.08; 0.66; 0.38 ratio
Influenza
Primary: Number of Participants Reporting Maternal Complications of Pregnancy, Labor and Delivery — 0; 0; 0; 0 participants
Antibiotic-Associated Diarrhea · Clostridium Difficile-Associated Diarrhea
Primary: To Assess if Probiotic Prophylaxis (BIO-K+CL1285®) is Effective for the Prevention of AAD in Hospitalized Patients. — 84; 85; 86 participants — p==0.02
Dry Eye Syndromes
Primary: Concentration of Cyclosporine Measured in Blood at Day 1 in the Parallel-Group Phase (PGP) — NA; NA; NA; NA Nanogram/milliliter (ng/mL)
Osteoporosis, Post-menopausal
Primary: Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months — 5.60; 0.16 percentage of surface — p=<0.001
Venous Thromboembolism
Primary: Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period — 3; 37 Participants — p=<0.0001
Colorectal Anastomosis
Primary: The Primary Endpoint is the Feasibility of the TachoSil® Application, Reported by the Combined Assessment of the Investigator and External Assessor — 1; 2; 1; 2…
Stroke
Primary: Stroke Rehabilitation Assessment of Movement (STREAM) — 73.1 units on a scale
Nasopharyngeal Cancer
Primary: Comparing the Level of Urinary N-telopeptide (uNTx) in the Two Arms . — 75; 94; 29; 88 nM /mM — p=0.370
Chronic Obstructive Pulmonary Disease
Primary: Exacerbation Rate — 1.20; 1.31 exacerbation per patient year — p=0.7282
Macular Degeneration
Primary: Mean Change of CR/LT From Baseline at Week 12 — -153.5; -75.6; -169.2; -56.3 μm
Cerebral Palsy
Primary: Changes in Motor Performance — 34.5; 38.2; 35.5; 7.00 units on a scale — p=<0.05
Human Immunodeficiency Virus
Primary: Total Number of Patients With Adverse Drug Reactions — 649; 67; 211; 130 participants
Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial · Urticaria
Primary: Number of Adverse Events Reported By Category After 14 Days of Treatment — 26; 21; 4; 1 Adverse Events
Head and Neck Cancer
Primary: Number of Patients Treated With ZD1839 With Chemotherapy and Hyperfractionated Radiation That Had a 1-year Survival — 52 participants